QIAGEN Enhances Digital PCR Lineup With New Lentivirus Tools for Cell and Gene Therapy QC In a move that further cements its position as a key player in the evolving field of cell and gene therapy (CGT), QIAGEN N.V.; Frankfurt…
Claritas Rx Unveils Groundbreaking Care Coordination Platform for Specialty and Rare Disease Patients In an era where healthcare delivery is increasingly fragmented, and specialty and rare disease patients often navigate complex treatment regimens, Claritas Rx, a leader in technology and…
LEAP Boosts Digital Lab Transformation with Key Executive Appointment in Clinical Diagnostics LEAP Consulting Group, a renowned boutique digital consultancy specializing in guiding national clinical diagnostic laboratories through complex, multi-phase digital transformations, has announced a strategic executive appointment that marks…
Contineum Therapeutics Names Timothy Watkins as CMO and Head of Development Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience, inflammation, and immunology (NI&I) disorders, today announced a significant leadership transition as part of its…
nChroma Bio to Present at ASGCT 2025 Annual Meeting nChroma Bio, an emerging leader in the field of genetic medicines, today announced the acceptance of three significant scientific abstracts at the 28th Annual Meeting of the American Society of Gene…
KEYTRUDA Plus Standard Therapy Boosts Event-Free Survival in Resectable Head and Neck Cancer Merck , known as MSD outside the United States and Canada, has announced landmark findings from its Phase 3 KEYNOTE-689 clinical trial evaluating the efficacy of KEYTRUDA®…
Gameto Launches First U.S. Clinical Site for Patient Enrollment in Fertilo Study Gameto, a clinical-stage biotechnology company at the forefront of developing cutting-edge iPSC (induced pluripotent stem cell)-based therapies to revolutionize fertility care, today announced an exciting milestone in its…
Gilead Sciences Reports Financial Results for First Quarter 2025 Gilead Sciences, Inc. (Nasdaq: GILD) has unveiled its financial and operational performance for the first quarter of 2025, underscoring a steady start to the year that reflects both commercial momentum and…
Creyon Bio Names Industry Veteran Serge Messerlian as CEO to Drive Growth and Partnerships Creyon Bio, a biotechnology company pioneering the use of artificial intelligence in oligonucleotide therapy development, has announced a major leadership transition with the appointment of Serge…
Pfizer Champions a New Era in Personalized Cancer Care at ASCO 2025 Annual Meeting Pfizer Inc. (NYSE: PFE), a global leader in biopharmaceutical innovation, announced its robust presence at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, which…
Halda Therapeutics Names Dr. Eyal Attar as New Chief Medical Officer Halda Therapeutics, a clinical-stage biotechnology company pioneering a new class of cancer therapeutics, has announced the appointment of Dr. Eyal Attar as its Chief Medical Officer (CMO). The strategic…
EditCo Bio and Promega Team Up to Advance Cell-Based Research In a pivotal move set to reshape the landscape of functional genomics and cell engineering, EditCo Bio, Inc. has announced a strategic licensing agreement with Promega Corporation. This collaboration grants…
